Background: Radiotherapy is an effective treatment for the postoperative loco-regional recurrence of esophageal cancer; however, the optimal treatment field remains controversial. This study aims to evaluate the outcome of local field radiotherapy without elective nodal irradiation for postoperative loco-regional recurrence of esophageal cancer. Methods: We retrospectively investigated 35 patients treated for a postoperative loco-regional recurrence of esophageal cancer with local field radiotherapy between December 2008 and March 2016. The median irradiation dose was 60 Gy (range: 50-67.5 Gy). Thirty-one (88.6%) patients received concurrent chemotherapy. Results: The median follow-up period was 18 months (range: 5-94 months). The 2-year overall survival was 55.7%, with a median survival time of 29.9 months. In the univariate analysis, the maximal diameter ≤20 mm (P = 0.0383), solitary lesion (P = 0.0352), and the complete remission after treatment (P = 0.00411) had a significantly better prognosis. A total of 27 of 35 patients (77.1%) had progressive disease (loco-regional failure [n = 9], distant metastasis [n = 7], and both loco-regional failure and distant metastasis [n = 11]). No patients had Grade 3 or greater mucositis. Conclusion: Local field radiotherapy is a considerable treatment option for postoperative locoregional recurrence of esophageal cancer.
Introduction
Surgical resection is the primary treatment choice for locally advanced esophageal cancer. However, 40-50% of operated patients suffer from recurrence (1-7) and loco-regional recurrence (LRR) is the most common pattern of failure (4-7).
To date, several reports have demonstrated the effectiveness of radiotherapy (RT) with or without chemotherapy for postoperative LRR of esophageal cancer (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . In most of these reports, irradiated fields with or without the inclusion of a prophylactic nodal area were analyzed. The optimal treatment field remains controversial.
At our institution, we have been treating patients who have had LRR of esophageal cancer following radical surgery with local field RT without elective nodal irradiation (ENI). There are no existing studies, to the best of our knowledge, reporting the treatment outcomes of RT for postoperative LRR of esophageal cancer only using local field RT. The purpose of this study was to evaluate the outcome of local field RT for postoperative LRR of esophageal cancer.
Materials and methods

Patients
Patients were included in this study when they met all of the following criteria: R0 resection for primary cervical or thoracic esophageal cancer; clinically diagnosed LRR on the basis of a biopsy or diagnostic imaging, such as computed tomography (CT) or positron emission tomography (PET)/CT; no distant organ metastasis; no history of RT; local field RT with or without chemotherapy between December 2008 and March 2016 at the University Hospital Kyoto Prefectural University of Medicine; and written informed consent before undergoing treatment. A total of 35 patients were included in this study. We retrospectively investigated the medical records of these patients.
The clinical data collected for each patient included sex, age, primary esophageal cancer location, pathological stage, histology of primary esophageal cancer, time interval between surgery and recurrence, recurrent sites, maximal diameter and number of recurrent lesions, irradiation dose and fractionation, concurrent chemotherapy regimens, tumor response to treatment, patterns of failure, and any treatment-related toxicities. The 7th edition of Union for International Cancer Control (UICC) classification was used to restage the primary disease after surgery.
This study was approved by the Institutional Review Board of Kyoto Prefectural University of Medicine.
Treatment
All patients underwent CT simulation. Three-dimensional conformal RT with a linear accelerator (4 or 6 or 10-MV) was applied to the treatment. The gross tumor volume (GTV) included recurrent lesions revealed by CT or PET/CT. The clinical target volume (CTV) was defined as the GTV plus a 5-10 mm radial margin. The prophylactic nodal area was not included in the CTV. The planning target volume (PTV) was defined as the CTV plus a 5-mm margin in all directions. Multiple field irradiation was used to deliver the radiation dose. The median irradiation dose for the PTV was 60 Gy (range: 50-67.5 Gy). The dose per fraction was 2-3 Gy; when the PTV was adjacent to the gastrointestinal tract, we used 2 Gy (standard fractionated RT; SF-RT), otherwise we used 2.25-3 Gy (hypofractionated RT; HF-RT). RT was delivered 5 days per week. The treatment fields were adjusted by multi-leaf collimator to reduce the maximal dose to the spinal cord <45 Gy. The percentage of lung volume receiving more than 5, 10, 20, 30 Gy (Lung-V 5 , V 10 , V 20 , V 30 ) and mean lung dose (MLD) were calculated. The percentage of heart volume receiving more than 10, 30, 50 Gy (Heart-V 10 , V 30 , V 50 ) and mean heart dose (MHD) were also calculated.
Thirty-one (88.6%) patients received concurrent chemotherapy. Physicians determined the usage and regimen of chemotherapy according to each patient's general condition and organ function (e.g., kidney, liver, heart and bone marrow).
Follow-up and assessment
Follow-up evaluations were performed every 3-6 months for the first 3 years and annually thereafter by visiting our department and referring physician, as well as undergoing an imaging examination with CT or PET/CT.
Regarding the transferred patients, the majority developed disease progression and were shifted to the best supportive care. We followed up the outcomes by mail to the medical facilities which accepted the patient.
Evaluation of the tumor response to treatment was performed 1-3 months after RT. The tumor response was recorded according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
Toxicities were graded according to the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). Adverse effects more than 90 days after the completion of RT were defined as late adverse effects.
Statistical analysis
We calculated the overall survival (OS), progression-free survival (PFS), and local control (LC) using the Kaplan-Meier method. The log-rank test was used to evaluate the statistical differences in OS. Sex, age (<70 years vs. ≥70 years), pathological stage (I-II vs. III-IV), interval between surgery and recurrence (≤6 months vs. >6 months), maximal diameter of lesions (≤20 mm vs. >20 mm), number of lesions (1 vs. 2≤), fractionation, biological effective dose (BED) (α/β = 10) (<75 Gy vs. ≥75 Gy), concurrent chemotherapy regimen, primary response to treatment (complete response vs. not complete response) were entered into the log-rank test. OS was defined as the time from start of RT to death of any cause. PFS was defined as the time from the start of RT to progression, relapse, or death of any cause. LC was defined as the time from start of RT to local progression or relapse.
P values <0.05 were considered statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) (21) .
Results
Patient characteristics
Patient characteristics are detailed in Table 1 .
Two patients had an anastomotic recurrence and regional LN recurrence. They were included in the multiple sites group. All Stage IV patients exhibited lymph node metastasis beyond the regional area and no distant organ metastasis.
Treatment outcome
The median follow-up period was 18 months (range: 5-94 months).
At the last follow-up, 18 patients (51.4%) had died. The 2-year OS was 55.7% (95% confidence interval (CI) = 35.5-71.9%) (Fig. 1) , with a median survival time of 29.9 months (95% CI = 18.3-49.4 months). The 2-year PFS was 15.8% (95% CI = 5.4-31.2%). The 2-year LC was 52.9% (95% CI = 33.0-69.3%).
The results of the univariate analysis for the patient characteristics and treatment factors are listed in Table 2 . The univariate analysis revealed that the maximal diameter (P = 0.0383), the number of lesions (P = 0.0352), and primary response to treatment (P = 0.00411) had statistically significant differences regarding the OS.
Patterns of failure
A total of 27 out of 35 patients (77.1%) had progressive disease after RT. The median interval between the start of RT to failure was 8.8 months (range: 1.8-64.1 months). The first progression sites are detailed in Table 3 . Six patients (17.1%) had an in-field failure with or without other lesions as the first failure.
Toxicities
The majority of the acute toxicities were Grade 1 or 2. Hematological toxicities were one of the most commonly observed acute adverse events. Grade 3 neutropenia/leucopenia and thrombocytopenia were observed in seven (20.0%) and one (2.9%) patients, respectively. The single patient with a Grade 4 event had a trachealesophageal-cutaneous fistula with hemorrhage, presumably due to shrinkage of the invasive tumor. Another patient had Grade 3 pneumonitis which was considered to be due to aspiration. Four (11.4%) patients had Grade 2 mucositis and no patients had Grade 3 or higher mucositis.
Regarding the late toxicities, three patients exhibited Grade 3 adverse events. One patient had a stricture of the anastomotic site which was located adjacent to the recurrent lesion and was included in the irradiation field. Grade 3 aspiration pneumonitis was observed in one patient. Another patient had Grade 3 anorexia.
Dose volume histogram parameters
The doses to lung of six patients and to heart of two patients were not available because of insufficient planning CT data. These patients had LRR of neck or abdominal region, and the doses to 
Discussion
Previous literature has shown that RT with or without concurrent chemotherapy for postoperative LRR of esophageal cancer is effective (8-20) ; however, the optimal method of RT remains controversial. Following the advancement of chemotherapeutic agents and radiotherapeutic techniques, the role of ENI is now an issue of discussion. The outcomes of previous studies are listed in Table 4 . In most of the previous studies, the outcomes of local field RT and ENI were analyzed together. The 2 and 3-year OS and median survival time (MST) were 22-60.2%, 0-51.8% and 7-43 months, respectively. For CRT, the 2 and 3-year OS and MST were 3360.2%, 10.5-51.8% and 13.3-43 months, respectively. In the present study, all patients were treated with local field RT, and the 2-year OS and MST were 55.7%, and 22.9 months, respectively. Thus, these results are comparable to those of previous studies, including ENI.
Jingu et al. referred to the irradiation field in their reports. They treated 11 patients with a T-shaped field (including the bilateral supraclavicular, mediastinal, and abdominal regions) and 19 with the local field, concluding that there was no benefit of T-shaped field irradiation; Grade 3 or higher acute adverse events were significantly more frequent with the T-shaped field (10) . Another paper by the same group studied solitary LN metastasis; two patients exhibited other LN metastasis following chemo-radiotherapy and both had undergone T-shaped field irradiation (9) . They concluded from these results that irradiation with a prophylactic field should not be recommended.
In the present study, two-thirds of progressive disease after RT involved distant metastasis as the first relapse, indicating that the tumor spread was hematogenous and was not thought to be preventable by ENI. Three out of nine patients who developed a relapse without distant metastasis experienced an in-field relapse. Thus, six (17.1%) patients exhibited failure only in the regional LN without an in-field relapse and distant metastasis, which might have been prevented if ENI was delivered. The patient characteristics and treatment factors of these six patients are listed in Table 5 . There is no obvious tendency of the patient characteristics and treatment factors. Four of these six patients received a second salvage RT for the relapsed lesion. Two of the patients lived without malignant disease for an extended period (31.5 and 66.6 months from the first RT), while two developed another relapse as a distant metastasis. Another two patients were treated with chemotherapy and finally died of esophageal cancer. Considering these patterns with failure, the role of ENI is considered to be quite limited. In addition, a second salvage RT should be considered when a regional LN relapse develops following a local field RT since the majority of the regional area was not previously irradiated.
The field size of the local field RT is smaller than that of RT with ENI. Thus, local field RT may have fewer toxicities than RT with ENI. In some previous reports including ENI, Grade 3 esophagitis or mucositis were observed in 3.3-27.3% patients (8, 19, 22) . The range of gastric tube irradiated by local field RT was narrow and no Grade 3 mucositis was observed in the present study. Although some patients survive for long periods after salvage RT, the late toxicity of RT for postoperative LRR of esophageal cancer has seldom been reported. In the studies on radical RT for (1) (2) (3) (4) (5) (6) (7) (8) (27) (28) (29) (30) (31) (32) (33) (34) . In the patients of the present study, the doses to OAR are extremely lower than the doses reported as predictive factors. Although the follow-up period in this study is not long enough to evaluate any late toxicities, we believe that local field RT will reduce the late cardiopulmonary toxicities caused by salvage RT. The small field of local field RT made it possible to safely use HF-RT unless the gastrointestinal tract was located adjacent to the PTV. We expected a superior treatment effect by HF-RT due to a higher BED with the same total irradiation dose. Indeed, in the present study HF-RT group had higher BED (α/β = 10) (median 78 Gy [74. 4-85.8 Gy]) than SF-RT group (median 72 Gy [60-76.8 Gy]) (P = 0.000000198; Mann-Whitney U test), although these two groups had almost the same total irradiation dose (HF-RT; median 60 Gy [60-67.5 Gy], SF-RT; median 60 Gy [50-64 Gy]) (P = 0.099; MannWhitney U test). However, there was no difference in the LC, OS and toxicity between HF-RT and SF-RT. Of course it is difficult to relate the fractionation to the treatment outcomes in the small number of patients, because not only BED but also other factors may affect the outcomes. At least in this study, the ratio of chemotherapy regimen (P = 0.0748; Fisher's exact test) and mean tumor diameter (P = 0.0671; t-test) in the two groups were not significantly different. We estimate that one of the reasons for the results is the treatment dose. In SF-RT, we primarily delivered an irradiation dose of 60 Gy in 30 fractions. This was sufficiently high dose, as Zhang et al. reported that an irradiation dose ≥60 Gy improves the treatment outcome (19) . To improve the treatment outcome, a dose escalation to more than 60 Gy or extremely hypofractionated RT might be required. However, Nemoto et al. reported that one patient died of necrosis of the gastric tube six months after 66 Gy radiotherapy (15) . We should be cautious about increasing the intensity of treatment. In addition, although there is no benefit regarding the effect of treatment, there is the advantage of a short treatment period associated with HF-RT.
Isolated LN recurrence has been reported as a better prognostic factor (35) (36) (37) (38) , which concurred with our data. In addition, all patients with multiple lesions developed distant metastasis, excluding one death due to other causes. This indicates that multiple lesions imply dissemination requiring systemic therapy.
This study has several limitations. First, this is a study with a small sample size and retrospective nature. Second, this is not a controlled study of an RT field with or without ENI. We cannot conclude that local field RT is not inferior to RT with ENI. Third, some factors other than the RT field, such as concurrent or adjuvant chemotherapy regimens, might have affected the pattern of relapse.
Local field RT is a considerable treatment option for postoperative LRR of esophageal cancer. However, prospective randomized studies on the RT field are needed to determine the optimal RT field.
